Bristol-Myers Squibb Co (BMY)

Industry Drug Manufacturers - General
This stock can be held in an Investment ISA and an Investment Account
Sell

$47.98

Buy

$47.99

arrow-up$0.77 (+1.63%)

Bristol-Myers Squibb Co is engaged in discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceuticals products. The company operates in one segment that is Biopharmaceuticals.
Prices updated at 20 May 2025, 15:23 BST
| Prices minimum 15 mins delay
|
Prices in USD
S&P 500
arrow-down-0.32%
NYSE
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
Our Investment Fees and Charges.

Income statement

Year
chevron-l-regular
chevron-r-regular
20172018201920202021202220232024
20,776m22,561m26,145m42,518m46,385m46,159m45,006m48,300m
14,762m16,094m18,067m30,745m36,445m36,022m34,313m34,332m
3,446m5,114m5,913m2,177m8,537m9,104m8,195m5,887m
16.5922.6722.625.1218.4019.7218.2112.19
1,007m4,920m3,439m-9,015m6,994m6,327m8,025m-8,948m
6,116m6,788m7,377m4,929m20,118m19,221m19,366m3,168m
Sales, General and administrative4,751m4,551m4,871m7,661m7,690m7,814m7,772m8,414m
Interest expenses196m183m656m1,420m1,334m1,232m1,166m1,947m
Provision for income taxes4,156m1,021m1,515m2,124m1,084m1,368m400m554m
Operating expenses11,316m10,980m12,154m28,568m27,908m26,918m26,118m28,445m
Income before taxes5,131m5,968m4,975m-6,871m8,098m7,713m8,440m-8,379m
Net income available to common shareholders1,007m4,920m3,439m-9,015m6,994m6,327m8,025m-8,948m
0.613.012.02-3.993.152.973.88-4.41
Net interest income-196m-183m-656m-1,420m-1,334m-1,232m-1,166m-1,947m
Advertising and promotion--------
Net investment income, net--------
Realised capital gains (losses), net--------
Total benefits, claims and expenses--------
Earnings per share (diluted)0.613.012.01-3.993.122.953.86-4.41
Free cash flow per share2.53972.26614.63445.30276.52375.8625.56556.8071
Book value/share9.09728.3997.92122.583517.284315.745114.34838.4485
Debt equity ratio0.5940720.4023950.853891.3000111.1261061.1692151.2974182.998041

Balance sheet

Year
chevron-l-regular
chevron-r-regular
20172018201920202021202220232024
Current assets14,854m17,160m29,354m30,192m33,262m27,273m31,770m29,780m
Current liabilities9,563m10,654m18,304m19,080m21,868m21,890m22,262m23,774m
Total capital18,716m19,677m94,985m86,158m75,551m66,117m66,083m63,938m
Total debt7,962m7,349m47,538m51,673m45,596m40,717m41,464m51,200m
Total equity11,741m14,031m51,598m37,822m35,946m31,061m29,430m16,335m
Total non current liabilities--------
Loans6,975m5,646m43,387m48,336m39,605m35,056m36,653m47,603m
Total assets33,551m34,986m129,944m118,481m109,314m96,820m95,159m92,603m
Total liabilities--------
Cash and cash equivalents5,421m6,911m12,346m14,546m13,979m9,123m11,464m10,346m
Common stock1,625m1,624m2,228m2,221m2,153m2,075m2,021m2,029m

Cash flow

Year
chevron-l-regular
chevron-r-regular
20172018201920202021202220232024
Cash at beginning of period4,237m5,421m6,911m12,820m14,973m14,316m9,325m11,519m
Cash dividends paid-2,577m-2,613m-2,679m-4,075m-4,396m-4,634m-4,744m-4,863m
4,220m4,989m7,231m13,299m15,234m11,948m12,651m13,942m
Investments (gains) losses-66m-874m-9,770m-10,859m-538m-1,062m-2,295m-21,352m
5,421m6,911m12,820m14,973m14,316m9,325m11,519m10,347m
Net income--------
5,275m5,940m8,067m14,052m16,207m13,066m13,860m15,190m
-1,055m-951m-836m-753m-973m-1,118m-1,209m-1,248m
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.